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Abstract: Insomnia affects a significant proportion of the general population and an even greater 
proportion of patients seen in general medical care. Insomnia has multiple negative effects 
on health status, decreases quality of life, and is associated with increased health care costs. 
Current treatments for insomnia include pharmacologic and behavioral strategies. Pharmacologic 
treatments may be effective for short-term and middle-of-the-night (MOTN) insomnia, but the 
usefulness of many sleep medications is limited by the residual daytime sedation with which 
they are associated. This problem is especially important in the case of MOTN insomnia, when 
only a few hours may elapse between the time a patient takes the medication and when he or 
she must rise. The development of sublingual and low-dose formulations of zolpidem raises the 
possibility that pharmacologic therapy may allow patients with MOTN insomnia to be effectively 
treated with a decreased risk of residual daytime sedation. Current studies of this strategy are 
promising, and several formulations are in the process of being brought to market.
Keywords: zolpidem, eszopiclone, zaleplon, insomnia
Insomnia, defined as difficulty in initiating and maintaining sleep or as having 
nonrestorative sleep, is a common problem with significant consequences for workplace 
productivity, public safety, and health.1 Although studies of insomnia prevalence have 
varied at least in part due to methodological differences, the report of the 2005 State of 
the Science conference convened by the US National Institutes of Health2 concluded that 
about 30% of the population reports sleep complaints and that 10% have symptoms of 
daytime impairment from insomnia. In clinical populations the prevalence of insomnia 
is much greater and is as high as 50%.2 More recently, a population-based poll by the 
US National Sleep Foundation found that significant numbers of persons report sleep 
difficulties. Almost one-third (29%) reported having difficulties in getting to sleep at 
least a few nights each week.3 Twenty-eight percent of respondents in this poll reported 
that they were awake “a lot” during the night almost every night, while another 18% 
reported a similar difficulty at least a few nights a week. Insomnia has profound func-
tional and economic consequences for those affected and for society. It is associated with 
significantly increased health care costs4 and has important effects on patients’ daytime 
functioning.5 In the elderly, insomnia is associated with the risk of development and for 
persistent depression6,7 and increased risk of mortality.8 In spite of varying estimates 
and the difficulties in ascertainment associated with self report of symptoms, it is clear 
that insomnia is a common problem that likely affects millions of persons.
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Insomnia is generally defined by the patients’ complaints 
of persistent difficulties in initiating or maintaining sleep 
or in having nonrestorative sleep. Clinicians distinguish 
among subtypes of insomnia based on how long the 
symptoms of insomnia have been present and the pattern 
of sleep disturbances. Although the time course and 
factors associated with the transition from short-term 
to chronic insomnia are not precisely def ined, the 
International Classification of Sleep Disorders9 defines 
short-term insomnia as having a duration of less than 
three months. Others have used various definitions of the 
time at which insomnia can be considered chronic,2 but in 
general short-term insomnia is defined as insomnia lasting 
1 to 3 months. If symptoms persist after this length of 
time the insomnia is considered chronic.9 Some persons 
with insomnia complain primarily of difficulties in getting 
to sleep but report that they sleep well after long sleep 
latencies. Other persons have difficulties in maintaining 
sleep and may awaken after sleeping several hours and then 
have difficulty returning to sleep. Although it is common 
to awaken during the night, most people have the ability 
to return to sleep once aroused. Difficulty in returning to 
sleep after a nocturnal awakening has been referred to as 
middle-of-the-night (MOTN) insomnia or as difficulty in 
returning to sleep insomnia. The causes of insomnia are 
diverse and may be associated with a biological predis-
position to hyperarousal as well as situational stressors 
and medical disorders.10 Further, the patterns of insomnia 
problems may vary over time, so that it may be important 
to be aware that patients’ primary complaints may vary 
over time.11
Spielman’s model of the development and continuation 
of insomnia distinguishes among factors that predispose to, 
initiate or maintain sleep difficulties.12 Persons with poor 
sleep habits or a tendency to worry, for example, may be 
at greater risk for developing insomnia, but insomnia itself 
may occur only after experiencing an acute stressor such as 
job loss or change in personal relationships. This short-term 
insomnia occurring in response to a stressor may resolve 
spontaneously without treatment, especially if the stressor 
resolves.
If other factors arise, however, the insomnia may 
become chronic. Patients may become preoccupied with 
their sleep, for example, and worry excessively about 
whether they will be able to sleep and if not how the lack 
of sleep might affect their functioning. Excessive worry 
may lead to the adoption of maladaptive behaviors such as 
sleeping late to make up for lack of sleep, daytime napping, 
and going to bed early without being able to go to sleep. All 
of these behaviors may result in even poorer sleep, greater 
worry about sleep, and the continuation of a vicious cycle 
of sustained poor sleep.
Factors that may lead to the perpetuation of insomnia 
include the adoption of maladaptive strategies to cope 
with sleep loss (such as spending excessive time in bed) or 
beginning to worry excessively about whether one will be 
able to sleep. Worry can then lead to still greater arousal 
at the very time when good sleep might be facilitated by 
relaxation. A vicious circle of worry and excessive time in 
bed may lead to even poorer sleep quality and the initial 
insomnia may become chronic.
MOTN insomnia is not precisely defined, but can 
generally be considered as persistent awakening after 
having fallen asleep with difficulty in returning to sleep. 
A variety of factors may contribute to MOTN insomnia. 
Environmental disturbances, a restless or noisy bed part-
ner, and need to use the toilet all may cause someone to 
awaken after having fallen asleep. Since the awakening 
may occur after several hours of sleep, sleep drive may be 
at a low level, making the return to sleep more difficult. 
Emotional reactions to having awakened, including upset 
at the cause of the awakening, can also contribute. Faulty 
sleep hygiene, such as leaving the television or radio on 
while falling asleep is still another potential contributor to 
MOTN insomnia. A careful sleep history is important in 
understanding patients’ complaints of both short-term and 
MOTN insomnia.
Intervening in the insomnia process
If one accepts the behavioral model of the factors related 
to the development of insomnia and its transition from to 
chronic or insomnia proposed by Spielman and colleagues,12 
a question logically arises about the optimal means of treating 
short-term insomnia. Possible strategies might range from 
watchful waiting, as it is likely that a substantial number of 
persons with short-term insomnia may have complaints that 
improve with time. An alternative might be to intervene 
aggressively in those with short-term insomnia in order to 
prevent the development of chronic insomnia. If clinicians 
were able to determine when and how to intervene in the 
transition from acute to chronic insomnia, a substantial 
number of cases of chronic insomnia might be prevented 
from developing. Unfortunately, little information has 
accrued on the best ways to identify at-risk individuals 
and intervene in the process. One study suggested that it 
may be possible to identify vulnerable individuals with a 
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questionnaire that assesses the effect of stress on their sleep.13 
This form of secondary prevention might establish the utility 
of heightened surveillance of persons at risk for developing 
chronic insomnia and justify more aggressive interventions 
in primary care.
Treatment options  
for short-term insomnia
Treatment options for short-term insomnia include both 
behavioral and pharmacologic interventions. Cognitive 
behavioral treatment of insomnia has demonstrated 
efficacy,14–16 but its use is limited by the availability of 
qualified practitioners. Many clinicians have few options 
for employing behavioral interventions for insomnia and 
may have difficulty identifying qualified persons to whom 
interested patients can be referred. Limited reimbursements 
for behavioral interventions for sleep disorders may also 
limit the willingness of practitioners to provide these 
services.17 Although behavioral treatments thus are effective 
for insomnia, the limited number of qualified practitioners 
limits the availability of this treatment in many situations. 
For many clinicians, the most readily available treatment for 
short-term insomnia may be pharmacotherapy.
One of the most common interventions for short-term 
insomnia is thus pharmacotherapy with a hypnotic agent. 
Currently available therapies include benzodiazepines, non-
benzodiazepine GABAergic medications, the melatonin 
receptor agonist ramelteon, and sedating antidepressants.18 
Many patients report use of over-the-counter medications 
most of which contain antihistamines but evidence suggests 
that while the sedating effect of antihistamines may be 
helpful for a few days it becomes indistinguishable after 
several days.19 Probably the most commonly used sedating 
antidepressant is trazodone, but evidence for its efficacy is 
limited and it may have significant adverse effects.20
Benzodiazepines are often used to treat short-term 
insomnia but clinicians may be concerned about the 
possible development of tolerance in some patients. Little 
specific information is available to guide the choice of 
one agent over another in short-term insomnia, although 
clinician preferences and concerns about the development of 
dependence may be important factors in medication selection. 
Clinicians are increasingly likely to prescribe one of the non-
benzodiazepine GABAergic medications such as zolpidem, 
eszopiclone, or zaleplon in preference to benzodiazepines. 
Although effective and safe pharmacologic treatments are 
available for insomnia, the prescribing information for most 
medications such as zolpidem include the recommendation 
that it be taken only when the user will be able to devote 
8 hours or more to sleep. This recommendation arises from 
the potential residual daytime sedating effects of medications 
for insomnia. In addition, most current pharmacotherapeutic 
agents do not have demonstrated efficacy in promoting 
sleep maintenance, although formulations of zolpidem and 
eszopiclone may be useful in promoting sleep throughout 
the night.21
As noted, MOTN insomnia arises in individuals who 
may have little or no difficulty in initiating sleep but 
who awaken after several hours and then have difficulty 
returning to sleep. As noted above, a significant number 
of persons may complain of nocturnal awakenings fol-
lowed by protracted wakefulness. A challenge in treating 
this prevalent form of insomnia arises from the length of 
action of medications typically used for insomnia, including 
benzodiazepines such as temazepam or nonbenzodiazepine 
GABAergic agents such as zolpidem. These medications 
have half-lives that range from 1.4 to 4.5 hours for zolpidem 
to more than 20 hours for several of the benzodiazepines. 
Even those medications with short half lives may have 
significant residual daytime sedating effects when used for 
MOTN insomnia.
Sleep medications may have significant residual daytime 
effects that affect cognitive skills such as reaction time, motor 
coordination and memory.22 These skills may be particularly 
relevant to driving an automobile, a skill that may often be 
used by insomnia patients in the morning after having taken 
a medication. Several studies have shown that medications 
such as zolpidem may have significant negative impacts on 
real-world driving ability after having been taken at night.23,24 
It is thus unsurprising that several studies have used driving 
as a criterion for evaluating the morning after effects of 
insomnia medication use.
In one study, both the long half-life drug flurazepam 
and the shorter half life drug temazepam had significant 
effects on driving 12 hours after they had been taken. Betts 
and Birtle25 evaluated the effect of single doses of either 
flurazepam 15 mg or temazepam 20 mg administered in 
counter-balanced order on driving performance on a closed 
course. The driving performance of 12 participants, all of 
whom were women, was evaluated in the morning between 
9.00 and 11.00 AM, 12 hours after they had taken the drug. 
Participants in each condition displayed substantially more 
driving errors in driving over a course with barriers that 
required weaving or the equivalent of changing lanes. These 
results thus show that residual daytime effects on driving 
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performance may be present even with the relatively shorter 
half-life medication temazepam.
Some evidence has accumulated for similar residual effects 
of the non-benzodiazepine drugs. In a controlled environment, 
Partinen et al26 gave zolpidem 10 mg, temazepam 20 mg, or 
placebo to women with insomnia at 2.00 AM and studied their 
performance in a driving simulator at 7.30 AM, 5.5 hours after 
taking the medication. A battery of computer-administered 
neuropsychological measures was completed in the morning 
and polysomnographies (PSGs) were done each night. Par-
ticipants were 23 women with primary insomnia as defined as 
having a) complaint of difficulty in initiating or maintaining 
sleep, or of nonrestorative sleep, for 1 month; b) the sleep dis-
turbance or related daytime fatigue caused clinically significant 
impairment, and c) the sleep disturbance did not occur in the 
context of other disorders. All were between 35 and 60 years 
of age (mean age 49.5 years), had driver’s licenses for at least 
5 years, and reported driving at least 5000 km each year.
The primary endpoint for the study was the mean time to 
a collision in the driving simulator, a variable that reflected 
sustained attention and reaction time in the driving simulator. 
No group differences were found across conditions (placebo, 
zolpidem, temazepam) in mean time to a collision. In 
secondary endpoints, neither reaction time nor memory score 
showed significant group differences, however, a significant 
effect was found for zolpidem in a measure of how well the 
person was able to maintain lane control over 100 km of 
simulated driving. Although these group results suggest little 
effect of the drugs on driving and memory performances, 
the authors of this study note that they observed substantial 
interindividual differences in performance that were possibly 
clinically significant. Several patients had simulator accidents 
after taking temazepam and zolpidem. The total number 
of accidents in the driving simulator, for example, was 
6 for participants in the drug conditions but only 1 in the 
baseline and placebo conditions. Several participants thus 
showed much worse performance in the simulator after 
drug administration, suggesting that some individuals make 
be substantially impaired even 5.5 hours after ingestion of 
either temazepam or zolpidem. Clinicians should therefore 
be alert to the possibility that some individuals may be highly 
susceptible to residual effects of sleep medications and 
exercise appropriate caution in prescribing them for patients 
who may have to engage in complex mental activities the 
morning after taking them.
Another study27 compared the residual daytime sedating 
effects of either zaleplon 10 mg or zolpidem 10 mg after 
MOTN awakening. Thirty-seven adults with insomnia (mean 
age 44 years) received either a medication or placebo four 
hours after bedtime, and residual sedation was evaluated by 
sleep latency tests at hourly intervals after they awakened 
4 hours later and for up to 7 hours after taking the medication. 
Residual effects of the medications were assessed through 
repeated sleep latency tests as well with self-reports of 
concentration ability and the Digit Symbol Substitution Test 
(DSST). The DSST is a paper and pencil test that requires 
individuals to rapidly substitute numbers in a series of boxes 
according to a key while their performance is timed. It is often 
considered a measure of psychomotor speed and attention that 
is sensitive to the effects of a sedating medication. Persons 
receiving the 10 mg dose of zolpidem showed significant 
effects on the sleep latency test, self-report of concentration, 
and DSST compared to zaleplon 10 mg and placebo for up 
to 7 hours after having received the drug. These results thus 
suggest that a standard dose of zolpidem (10 mg) may be 
associated with significant cognitive effects as long as seven 
hours after taking it.
Currently-available treatments for insomnia thus may 
pose significant risks for individuals’ alertness, psychomotor 
speed, and driving performance the morning after they are 
taken. These effects may be present in susceptible individuals 
for as long as 7 hours after taking a drug such as zolpidem, 
and it is possible that residual effects may be present for even 
longer periods if longer half life medications are used. It is 
thus clear that although currently available medications are 
clearly efficacious in promoting sleep onset in individuals 
with insomnia and may be useful in improving sleep 
maintenance, they may have lingering effects the morning 
after they are taken that have important implications for 
patients’ function and safety. The need for new agents that 
improve sleep while having little next-morning cognitive 
impairment are clearly needed.21
Treatment options  
for MOTN insomnia
Treatment options for MOTN insomnia include both 
behavioral and pharmacologic interventions. Hoch et al for 
example, showed that sleep restriction could improve sleep 
continuity in older persons, decreasing MOTN awakenings. 
Other studies have been consistent in suggesting that the 
behavioral technique of sleep restriction can improve sleep 
continuity. In this strategy, the patient is asked to keep a sleep 
diary for several weeks in order to determine the amount of 
time spent in bed and the amount of time actually spent in 
sleep. The patient is then asked to spend slightly less time in 
bed than he or she is usually asleep. This treatment strategy 
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has been shown to decrease MOTN awakenings in studies 
of chronic insomnia14 and might be expected to be effec-
tive in other contexts as well. As noted above, however, the 
limited availability of qualified persons to deliver behavioral 
sleep medicine services is an important drawback so that 
pharmacotherapy will continue to be an important option 
for MOTN insomnia as well.
Given the problems with residual daytime sedation and 
the possible effects of the time required for oral doses of sleep 
medications to take effect, the usefulness of several novel 
formulations of sleep medications have been investigated.28 
Given the possibility that sublingual administration might 
be associated with more rapid onset of action of zolpidem, 
several studies have evaluated this route of administration 
for this medication.
Staner et al29 investigated the utility of a sublingual 
formulation of zolpidem using it to assist in sleep initiation 
after participants had napped during the day. In this model 
of insomnia, having participants nap in the afternoon before 
later trying to reinitiate sleep served to reduce sleep drive 
so that the they would have difficulty in falling asleep. In a 
group of 21 healthy volunteers with a mean age of 26.7 years, 
2 doses of sublingual zolpidem (5 and 10 mg) were compared 
to a standard oral formulation of zolpidem (10 mg). Study 
results showed that the sublingual 10 mg dose produced 
shorter latencies to persistent sleep compared to the standard 
oral dose (12.8 vs 18.4 minutes) with similar effects on sleep 
onset latency and latency to stage one sleep. No significant 
group differences were observed for sleep maintenance 
variables or on subjective measures of sleep quality and 
all side effects were moderate or mild and resolved. These 
authors conclude that a sublingual formulation of zolpidem 
may be clinically useful given the reduction in time to sleep 
onset observed in this study.
Roth and colleagues30 evaluated the pharmacokinetic and 
pharmacodynamic characteristics of low-dose sublingual 
zolpidem. In this study, 24 participants (mean age 34.7 years, 
13 men and 11 women) who were healthy and without sleep 
complaints completed a double-blind, placebo-controlled 
crossover trial of the daytime sedating effects of 3 doses of 
sublingual zolpidem (1.0, 1.75, and 3.5 mg). The purpose of this 
study was thus to evaluate the sedating effects of several doses 
of zolpidem during the day, provide data on the time course of 
objective and subjective effects of the medication, and allow 
an investigation of the pharmacokinetic characteristics of these 
doses and their relation of the effects of the medication to its 
blood levels. Daytime sedation was measured objectively by 
the Digit Symbol Substitution Test (DSST) and subjectively via 
self-report ratings of sedation on a visual analog scale (VAS). 
Memory for words and reaction time were also measured 
to provide additional objective evaluations of the cognitive 
effects of the medication. Blood samples for pharmacokinetic 
evaluations were collected prior to the initial dose and for 
periods up to 12 hours after each dose.
Results of this study showed that both the 1.75 mg and 
3.5 mg dose, but not the 1.0 mg, of sublingual zolpidem 
showed significant sedating effects on the DSST at 20 minutes 
after drug administration. The effect of the 3.5 mg dose was 
substantially greater than that of the 1.75 mg dose on this 
measure. Significant effects of the medication compared 
to placebo lasted up to 90 minutes, although participants’ 
DSST scores did not return to levels essentially identical 
to those in the placebo group until 180 minutes after drug 
administration. Subjective reports of sedation paralleled 
results of objective testing, although participants’ reports of 
sedation did not return to baseline levels until 300 minutes 
after drug administration. The 3.5 mg dose showed maximum 
effects on reaction time at 20 minutes, while the 1.75 mg and 
1.0 mg doses showed maximum change at 1 hour. For the two 
lower doses, the observed change in reaction time was not 
statistically significantly different from placebo. On the word 
recall measure, the time of maximal change from placebo 
was 20 minutes for the 3.5 mg dose but 1 hour for the 1.75 
and 1.0 mg doses. Here again, the changes from baseline for 
the lower two doses were not significantly different from 
placebo levels. Pharmacokinetic analyses showed that for 
these participants the maximal drug concentration and areas 
under the curve were proportional to the dose. The half-life 
of zolpidem was slightly longer than 2.3 to 2.5 hours, with a 
time to maximal concentration of 36 to 38 minutes.
A pharmacokinetic study with elderly persons was 
presented by Krystal et al (reported in Lankford31). In that 
study, the pharmacokinetics of sublingual zolpidem were 
studied in healthy elderly volunteers. In the elderly, at the 
3.5 mg dose both the maximum concentration and the area 
under the curve were elevated relative to younger adults. 
The 1.75 mg dose in the elderly resulted in maximum 
concentrations and areas under the curve that were somewhat 
lower than those found in younger adults. The elimination 
half-life, however, was similar for older as well as younger 
persons. Lankford suggests that this finding supports the 
recommendation that the lower dose of sublingual zolpidem 
may be most appropriate as a starting point for older 
persons.31
In another study, Roth and colleagues32 report a 
randomized, double-blind, placebo-controlled, three-way 
Nature and Science of Sleep 2010:268
Ownby Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
crossover trial of sublingual zolpidem tartrate in 82 adults 
(mean age = 45.9 years; 24 men and 58 women) with a 
DSM-IV diagnosis of primary insomnia and a history of 
MOTN insomnia with an average of 2.2 awakenings per night. 
Individuals were eligible to participate if, in a preliminary 
evaluation, they showed PSG evidence of prolonged time 
in returning to sleep after a scheduled MOTN awakening. 
Individuals participated in three treatment episodes consisting 
of two consecutive nights of dosing with placebo, sublingual 
zolpidem 1.75 mg, or sublingual zolpidem 3.5 mg. Dose of 
placebo or medication was administered after awakening 
the participants four hours after initial lights out (without 
regard to the participant’s sleep stage at time of awakening). 
Treatment episodes were separated by a 5- to 12-day washout 
period and delivered in a randomization sequence in which all 
participants received each treatment condition. The primary 
efficacy variable was the participant’s average latency to 
persistent sleep after the MOTN awakening.
Study results showed significant effects of both doses of 
sublingual zolpidem on key sleep parameters. Both doses 
of zolpidem were associated with a significant decrease in 
PSG-measured latency to persistent sleep (from a mean of 
28.1 minutes for placebo to 16.9 and 9.7 minutes for the 1.75 
mg and 3.5 mg doses of zolpidem, respectively) as well as in 
patient-reported sleep onset latency. Both doses of zolpidem 
were associated with significant increases in total sleep time 
both as measured by PSG and patient report. The 3.5 mg 
dose of zolpidem was associated with significantly better 
ratings of sleep quality in comparison to placebo, as well as 
in ratings of level of refreshed sleep and ability to function 
the next day.
This study included evaluation of the objective and 
subjective effects of zolpidem treatment on morning 
functioning. Participants completed the DSST and a visual 
analog scale (VAS) asking for self-report of level of sedation 
on each morning of the treatment periods. Results of this 
evaluation showed that neither DSST performance nor the 
VAS ratings differed significantly across conditions five 
hours after administration of zolpidem or placebo. It may 
be noted, however, that subjects reported some subjective 
sedation up to 5 hours after medication administration. 
Differences between groups at 5 hours, however, were not 
significantly different. It is thus not clear precisely how long 
patients must sleep to avoid any subjective morning sedation. 
No serious side effects were noted in this study, although 
14 of the 82 participants reported at least one adverse event 
during the study. All adverse events were mild and of short 
duration, allowing the authors to suggest that sublingual 
zolpidem may be a safe and effective treatment for MOTN 
insomnia.
Conclusion
Studies of sublingual zolpidem thus show that this form 
of the drug is likely to be effective in short-term insomnia. 
This dosing form’s rapid onset of action may confer benefits 
for patients taking the medication at typical bedtimes, as 
shown in the study by Staner et al.29 Standard doses may 
be associated with clinically significant residual daytime 
sedation so that standard doses may not be safely used in 
patients with MOTN insomnia. At lower doses, however, the 
residual daytime effects of zolpidem may be reduced and it 
may thus be useful in MOTN insomnia. It should be noted, 
however, that at least one study suggested that the subjective 
sedating effects of zolpidem persisted as long as five hours 
after dosing, a factor that may be important depending on time 
of administration and time of arising. Still, although standard 
5 and 10 mg doses may be associated with morning sedation 
if taken after midnight,27 lower doses of sublingual zolpidem 
may be less likely to cause morning sedation and may thus 
be useful for treating short-term insomnia characterized by 
difficulty in initiating sleep and in MOTN insomnia.
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